Practical Treatment Strategies for the Successful Management of Bipolar Disorder
A supplement to Clinical Psychiatry News and supported by Lilly.
This supplement has been developed based on the "New Clinical Strategies for the Recognition and Treatment of Bipolar Disorder: Can We Successfully Advance Care?" program that took place on September 14-15, 2007, in San Antonio, Texas. The intent is to provide best practices to clinicians relative to the diagnosis and treatment of bipolar disorder across the life span.
To view the supplement, click the image above. To take the CME Posttest, download and print out the CME Posttest PDF file, and follow the test instructions.
FACULTY
Robert M.A. Hirschfeld, MD
Co-Chair
Titus H. Harris Chair,
Harry K. Davis Professor,
Professor and Chair
Department of Psychiatry and Behavioral Sciences
The University of Texas Medical Branch
Galveston, Tex.
Dr Hirschfeld is a consultant and/or has participated in advisory boards for Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Jazz Pharmaceuticals, KV Pharmaceutical, Novartis, Organon, Ortho-McNeil, Pfizer, Shire, Solvay Pharmaceuticals, and Wyeth-Ayerst.
Karen Dineen Wagner, MD, PhD
Marie B. Gale
Centennial Professor and Vice Chair
Department of Psychiatry and Behavioral Sciences
Director, Division of Child and Adolescent Psychiatry
The University of Texas Medical Branch
Galveston, Tex.
Dr Wagner receives grant/research support from the National Institute of Mental Health (NIMH) and is a consultant and/or has participated in advisory boards for Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Janssen Pharmaceutica, Novartis, and Otsuka.
S. Nassir Ghaemi, MD, MPH
Associate Professor of Psychiatry and Public Health
Director, Bipolar Disorder Research Program
Emory University
Atlanta, Ga.
Dr Ghaemi receives research grants from, has participated in advisory boards for, and/or is on the speaker’s bureau for Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Janssen Pharmaceutica, Pfizer, and Shire.
Charles L. Bowden, MD
Co-Chair
Nancy U. Karren Chair of Psychiatry
Clinical Professor of Psychiatry and Pharmacology
The University of Texas Health Science Center at San Antonio
San Antonio, Tex.
Dr Bowden receives research grants from, is a consultant for, and/or is on the speaker’s bureau for Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Elan Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Lilly Research Laboratories, The NIMH, Parke-Davis, Pfizer, R.W. Johnson Pharmaceutical Research Institute, SmithKline Beecham, The Stanley Medical Research Institute, Sanofi-Synthélabo, and UCB Pharma.
TARGET AUDIENCE
This activity has been designed to meet the educational needs of psychiatrists, primary care physicians, and clinical psychiatry nurses.
EDUCATIONAL NEEDS
There continues to be a critical need for better recognition and diagnosis of bipolar disorder by clinicians in both psychiatry and primary care. There is also a mandate for new clinical strategies informed by the latest research in treating individuals with bipolar disorder.
LEARNING OBJECTIVES
Upon completion of this educational activity, participants should be able to:
• Refine their diagnostic skills with an expanded understanding of the differential diagnosis of the bipolar spectrum and unipolar depression
• Review the latest clinical evidence and treatment strategies in bipolar disorder
• Delineate the clinical approaches for short-term vs long-term management of bipolar disorder
• Consider the complexities of bipolar disorder in adults and children, with a better understanding of the variety of associated comorbidities and clinical presentations
• Recognize and diagnose bipolar disorder as early as possible
• Apply appropriate treatment strategies in an effort to prevent recurrence and limit or eliminate all symptoms.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The University of Texas Health Science Center at San Antonio School of Medicine (UTHSCSA School of Medicine) and Health & Wellness Education Partners. The UTHSCSA is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
The UTHSCSA School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Term of Approval: January 2008 - January 31, 2009.
